Article
Louisville, Ky. - A drug indicated for the treatment of periodontal disease appears to have efficacy equivalent to conventional oral therapy for rosacea but with virtually none of the side effects.
Reflecting on the Growth of NPs and PAs in Dermatology
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Bridging Therapeutic Innovation and Dermatology
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Nektar Therapeutics Completes Enrollment for Phase 2b REZOLVE-AD Trial of Rezpegaldesleukin
Study Reveals Immune Checkpoint Inhibitor Treatment and Monitoring Practices Post-Remission